Janssen acquires rights for geographic atrophy gene therapy
Janssen Pharmaceuticals has acquired the rights to HMR59, an investigational one-time intravitreal injection gene therapy being developed for the treatment of geographic atrophy, from Hemera Biosciences, according to a press release.
The therapy is intended to increase the ability of retina cells to make a soluble form of CD59, a protein that protects the retina from damage, thereby preventing damage and saving sight, the release said.
A phase 1 study of the therapy in geographic atrophy is complete, with a second phase 1 study in wet age-related macular degeneration underway.
“With the potential to transform how AMD is managed, HMR59 fulfills a key area of focus for Janssen, widens the company’s focus to more common eye diseases and serves as an important driver for long-term company growth,” James F. List, MD, PhD, global therapeutic area head, cardiovascular and metabolism, Janssen Research and Development, told Healio/OSN.
Financial details of the acquisition were not disclosed.